Cellectar Biosciences CLRB 深 沪
已收盘 10-02 16:00:00 美东时间
1.78
-0.090
-4.81%
华盛通- 最 高1.975
- 今 开1.95
- 成交量 4.80万股
- 最 低 1.78
- 昨 收 1.87
- 总市值 1682.48万
- 52周最高 5.069
- 市盈率 静 --
- 换手率 0.51%
- 52周最低 1.78
- 委 比 69.53%
- 总股本 945.21万
- 历史最高 276000.00
- 量 比 0.63
- 振 幅 10.43%
- 历史最低 1.78
- 每 手 1
- 风险率 0.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
Cellectar Biosciences 13G Filing Shows Balyasny Asset Management Reports 9.99% Stake In Co As Of June 30, 2026, Holding 798,382 Shares And Warrants
08-15 00:17
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
Cellectar Biosciences 13G Filing Shows StemPoint Capital Reports 9.99% Stake In Co As Of June 30, 2026, Holding 845,740 Shares Including Pre-Funded Warrants
08-15 00:17
Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over losses of $(3.39) per share from the same period last year.
08-13 19:03
Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MM
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across Multiple B-Cell Malignancies FLORHAM PARK, N.J., July 15, 2026 (GLOBE NEWSWIRE) ...
07-15 19:33
Cellectar Biosciences Shareholders Approve Key Governance Measures
An announcement from Cellectar Biosciences ( ($CLRB) ) is now available. At its...
07-11 05:28
Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyPlans to Initiate Phase 3 Confirmatory
06-01 20:15
Cellectar Biosciences Bets on Iopofosine Breakthrough
Cellectar Biosciences Inc (($CLRB)) has held its Q1 earnings call. Read on for ...
05-20 13:19
Cellectar Biosciences Announces Board Changes and New Director
The latest announcement is out from Cellectar Biosciences ( ($CLRB) ). On May 1...
05-19 06:01
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
